Glioblastoma (malignant brain tumors) are difficult to treat and the life expectancy for patients is short, therefore development of better treatments is essential. An altered sensitivity for EGFR (epidermal growth factor receptor) is observed in many glioblastoma, but the genetic change is different than for other cancers that are sensitive to EGFR inhibitors.
With current research scientists will analyze both the different mutations that could influence the functioning of EGFR and they will analyze the effects of stimulation and inhibition of EGFR.
Obtaining more insight why the EGFR mutations, associated with glioblastoma, are different and how their function could be influenced is needed to develop new treatments. New treatments for glioblastoma are important given the low success rate of current treatments and short life expectancy of patients.